Xevant: Pioneering Data Analytics for a More Efficient Pharmacy Benefit Landscape

Xevant, Inc, a company dedicated to revolutionizing the pharmacy benefit landscape, recently announced their commitment to accelerated growth with a significant follow-on investment. This financial backing underscores the growing recognition of their innovative data analytics platform designed to help pharmacy benefit organizations (PBMs) navigate the complexities of the healthcare system.

PBMs play a crucial role in managing prescription drug costs for various stakeholders, including employers, health plans, and individual consumers. However, navigating the intricate world of pharmacy benefits can be challenging due to complex data analysis and reporting requirements.

Xevant addresses this challenge by providing automated data analytics and reporting tools specifically tailored for PBMs. This innovative platform empowers PBMs with the ability to:

  • Gain deeper insights: Xevant’s technology analyzes vast amounts of data related to drug utilization, pricing, and trends, providing PBMs with a comprehensive understanding of their clients’ needs and opportunities for cost savings.
  • Make informed decisions: Armed with these insights, PBMs can make data-driven decisions regarding drug formularies, network contracting, and other vital aspects of their operations.
  • Improve efficiency: Xevant’s platform automates various tasks, streamlining workflows and freeing up valuable time for PBM teams to focus on strategic initiatives.

By leveraging Xevant’s cutting-edge technology, PBMs can not only reduce costs but also enhance the overall quality of care for their clients. This translates to improved health outcomes, increased affordability, and a more efficient healthcare system for everyone involved.

Xevant’s commitment to innovation extends beyond their initial product offering. They continuously invest in research and development to further enhance their platform and stay at the forefront of the ever-evolving healthcare landscape. This dedication to progress ensures that PBMs can rely on Xevant to provide them with the tools they need to navigate the complexities of the pharmaceutical industry and deliver optimal results for their clients.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Recent Posts